The evERA trial met both co-primary endpoints, showing statistically significant and clinically meaningful improvements in progression-free survival in both the overall and ESR1-mutated populations. How do you interpret the magnitude of these benefits, and what does this mean for patients progressing after CDK4/6 inhibition?

Given that Giredestrant acts as both an estrogen receptor antagonist and degrader, how might its dual mechanism provide an advantage over traditional endocrine therapies, particularly in tumors with ESR1 mutations or endocrine resistance?

The evERA study tested Giredestrant in combination with everolimus, an mTOR inhibitor. What are the clinical and biological rationales for this combination, and how might it reshape the post-CDK4/6 standard of care compared to current endocrine therapy plus everolimus regimens?

The improvement in progression-free survival among patients with ESR1 mutations was a key outcome in evERA. How do you contextualize this result against emerging oral SERDs in the same space, and could ESR1 status soon guide more routine treatment selection in clinical practice?

With multiple oral SERDs now in late-stage development, what differentiates Giredestrant based on the data from evERA? Are there any specific efficacy or tolerability advantages that could position it as a preferred agent in the evolving endocrine therapy sequence?

Safety and tolerability are critical considerations in the chronic management of advanced ER-positive breast cancer. What have we learned from evERA about the safety profile of Giredestrant plus everolimus, and how does it compare to existing treatment backbones?

As oncologists increasingly face patients who have progressed on CDK4/6 inhibitors, how might evERA’s results influence treatment sequencing strategies? Do these data suggest that SERD-based regimens could become a more prominent second-line option?

Giredestrant is also being evaluated in other combinations, such as with PI3K inhibitors like inavolisib. How important are these ongoing studies in defining Giredestrant’s full therapeutic potential across treatment lines, and do you foresee a move toward personalized combination strategies guided by tumor biologyy?